Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRR1 | P24046 | 2/20 | 0.54 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | MGAM | O43451 | 1/20 | 0.37 |
| ▸ | SI | P14410 | 1/20 | 0.37 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.37 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | GABBR2 | O75899 | 2/20 | 0.37 |
| ▸ | GABBR1 | Q9UBS5 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7879761 | 1.00 | GABRR1 (0.54) | GABRR1CPB2CYP1A2ALOX15ALDH1A1 | |
| SCHEMBL30360217 | 0.98 | GABRR1 (0.52) | GABRR1CPB2CYP1A2ALOX15ALDH1A1 | |
| SCHEMBL28212354 | 0.98 | GABRR1 (0.52) | GABRR1CPB2CYP1A2ALOX15ALDH1A1 | |
| SCHEMBL28212355 | 0.98 | GABRR1 (0.52) | GABRR1CPB2CYP1A2ALOX15ALDH1A1 | |
| SCHEMBL9411898 | 0.87 | CPB2 (0.51) | GABRR1CPB2CYP1A2ALOX15ALDH1A1 | |
| SCHEMBL14616914 | 0.85 | ALDH1A1 (0.48) | GABRR1CPB2CYP1A2ALOX15ALDH1A1 | |
| SCHEMBL16125818 | 0.85 | CPB2 (0.59) | GABRR1CPB2CYP1A2ALOX15ALDH1A1 | |
| SCHEMBL518315 | 0.85 | CPB2 (0.59) | GABRR1CPB2CYP1A2ALOX15ALDH1A1 | |
| Hydrochloric Acid SCHEMBL28252625 | 0.85 | CPB2 (0.50) | GABRR1CPB2CYP1A2ALOX15ALDH1A1 | |
| SCHEMBL9343926 | 0.84 | ALDH1A1 (0.42) | GABRR1CPB2CYP1A2ALOX15ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240115536-A1 | DUAL-ACTING PHARMACEUTICAL COMPOSITIONS BASED ON SUPERSTRUCTURES OF ANGIOTENSIN RECEPTOR ANTAGONIST/BLOCKER (ARB) AND NEUTRAL ENDOPEPTIDASE (NEP) INHIBITOR | NOVARTIS AG (CH) | 2024-04-11 | — | — | US | claimed |
| EP-3943084-A1 | NEP INHIBITORS FOR TREATING DISEASES CHARACTERIZED BY ATRIAL ENLARGEMENT OR REMODELING | Novartis AG (CH) | 2022-01-26 | — | — | EP | claimed |
| CN-108685889-A | Nep inhibitor for treating the disease for being characterized as atrial enlargement or reconstruct | 诺华股份有限公司 | 2018-10-23 | — | — | CN | claimed |
| CN-101516831-B | Process for preparing biaryl substituted 4-amino-butyric acid or derivatives thereof and their use in production of NEP inhibitors | NOVARTIS AG | 2013-12-25 | — | — | CN | claimed |
| CN-102091330-A | Pharmaceutical compositions comprising valsartan and NEP inhibitors | NOVARTIS AG | 2011-06-15 | — | — | CN | claimed |
| EP-1951309-A2 | COMBINATION OF AN ANGIOTENSIN II RECEPTOR BLOCKER, A CALCIUM CHANNEL BLOCKER AND ANOTHER ACTIVE AGENT | Novartis AG (CH) | 2008-08-06 | — | — | EP | claimed |
| WO-2007056324-A2 | COMBINATION OF AN ANGIOTENSIN II RECEPTOR BLOCKER, A CALCIUM CHANNEL BLOCKER AND ANOTHER ACTIVE AGENT | NOVARTIS AG (CH) | 2007-05-18 | — | — | WO | claimed |
| CN-1615134-A | Pharmaceutical composition comprising valsartan and NEP inhibitor | NOVARTIS AG (CH) | 2005-05-11 | — | — | CN | claimed |
| US-20250339395-A1 | COMPOUNDS CONTAINING S-N-VALERYL-N-{[2'-(1H-TETRAZOLE-5-YL)-BIPHENYL-4-YL]-METHYL}-VALINE AND (2R,4S)-5-BIPHENYL-4-YL-4-(3-CARBOXY-PROPIONYLAMINO)-2-METHYL-PENTANOIC ACID ETHYL ESTER MOIETIES AND CATIONS | NOVARTIS PHARMACEUTICALS CORP (US) | 2025-11-06 | — | — | US | disclosed |
| US-20250325518-A1 | USE OF A COMBINATION OF SACUBITRIL AND VALSARTAN | NOVARTIS AG (CH) | 2025-10-23 | — | — | US | disclosed |
| EP-4609912-A2 | NEW USE OF A COMBINATION OF SACUBITRIL AND VALSARTAN | Novartis AG (CH) | 2025-09-03 | — | — | EP | disclosed |
| EP-4570314-A2 | SACUBITRIL-VALSARTAN DOSAGE REGIMEN FOR TREATING CHRONIC SYSTOLIC HEART FAILURE | Novartis AG (CH) | 2025-06-18 | — | — | EP | disclosed |
| EP-3411021-B1 | NEW USE OF A COMBINATION OF SACUBITRIL AND VALSARTAN | NOVARTIS AG (CH) | 2025-05-14 | — | — | EP | disclosed |
| EP-4212152-B1 | SACUBITRIL-VALSARTAN DOSAGE REGIMEN FOR TREATING CHRONIC SYSTOLIC HEART FAILURE | NOVARTIS AG (CH) | 2025-04-30 | — | — | EP | disclosed |
| WO-2010136474-A2 | SUBSTITUTED AMINOBUTYRIC DERIVATIVES AS NEPRILYSIN INHIBITORS | NOVARTIS AG (CH) | 2010-12-02 | — | — | WO | disclosed |
| CN-101848700-A | Dual action pharmaceutical composition based on a superstructure of angiotensin receptor antagonists/blockers (ARBs) and Neutral Endopeptidase (NEP) inhibitors | NOVARTIS AG | 2010-09-29 | — | — | CN | disclosed |
| CN-101631765-A | Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid | NOVARTIS AG | 2010-01-20 | — | — | CN | disclosed |
| CN-101516831-A | Process for preparing biaryl substituted 4-amino-butyric acid or derivatives thereof and their use in the production of NEP inhibitors | NOVARTIS AG (CH) | 2009-08-26 | — | — | CN | disclosed |
| CN-101151027-A | Combination of organic compounds | NOVARTIS AG (CH) | 2008-03-26 | — | — | CN | disclosed |
| CN-1615134-A | Pharmaceutical composition comprising valsartan and NEP inhibitor | NOVARTIS AG (CH) | 2005-05-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240115536-A1 | DUAL-ACTING PHARMACEUTICAL COMPOSITIONS BASED ON SUPERSTRUCTURES OF ANGIOTENSIN RECEPTOR ANTAGONIST/BLOCKER (ARB) AND NEUTRAL ENDOPEPTIDASE (NEP) INHIBITOR | ACE, MME, AGTR1 | GABRR1 1848/4885CPB2 768/4885CYP1A2 1478/4885 |
| US-20250325518-A1 | USE OF A COMBINATION OF SACUBITRIL AND VALSARTAN | MME, ACE, REN | GABRR1 1731/4885CPB2 422/4885CYP1A2 1635/4885 |
| US-20250339395-A1 | COMPOUNDS CONTAINING S-N-VALERYL-N-{[2'-(1H-TETRAZOLE-5-YL)-BIPHENYL-4-YL]-METHYL}-VALINE AND (2R,4S)-5-BIPHENYL-4-YL-4-(3-CARBOXY-PROPIONYLAMINO)-2-METHYL-PENTANOIC ACID ETHYL ESTER MOIETIES AND CATIONS | MME, DNPEP, ANPEP | GABRR1 2256/4885CPB2 384/4885CYP1A2 2883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.